Small molecule-based inhibitors for treatment of tick-borne encephalitis virus infection: Nucleoside analogs and nonnucleoside antivirals
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00027162%3A_____%2F22%3AN0000251" target="_blank" >RIV/00027162:_____/22:N0000251 - isvavai.cz</a>
Alternative codes found
RIV/60077344:_____/22:00569226
Result on the web
<a href="https://www.sciencedirect.com/science/article/abs/pii/S0065774322000033?via%3Dihub" target="_blank" >https://www.sciencedirect.com/science/article/abs/pii/S0065774322000033?via%3Dihub</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/bs.armc.2022.08.003" target="_blank" >10.1016/bs.armc.2022.08.003</a>
Alternative languages
Result language
angličtina
Original language name
Small molecule-based inhibitors for treatment of tick-borne encephalitis virus infection: Nucleoside analogs and nonnucleoside antivirals
Original language description
More than 10,000 people a year become infected with TBEV, in which many cases are fatal. Despite the considerable medical importance of TBE, there is currently no approved antiviral treatment available to cure TBEV infections. Therefore, development of highly efficient and safe anti-TBEV drugs is an urgent medical need. Currently, numerous small molecule-based drugs are used to combat long-lasting/chronic viral infections, including those caused by HIV, HBV, HCV or HSV. Many of these antivirals, showing anti-TBEV activities, could be repurposed for the treatment of TBEV infections. However, it should be noted that small molecule-based treatments of acute viral infection, including TBE, could be somewhat challenging, as the serious/life-threatening symptoms of acute infections are very often a consequence of both viral replication in the host cells/tissues and the proinflammatory immune response combined with cytokine storms. The solution to this problem could be solved by a combination or sequential therapy based on application of both direct-acting antivirals, as well as antiinflammatory agents. Together with effective vaccination strategies specific small molecule-based therapy could provide a potent prophylactic and curative tools to combat human infections caused by TBEV.
Czech name
—
Czech description
—
Classification
Type
C - Chapter in a specialist book
CEP classification
—
OECD FORD branch
10607 - Virology
Result continuities
Project
<a href="/en/project/LTAUSA18016" target="_blank" >LTAUSA18016: Search for novel nucleoside analogs as antivirals against medically important flaviviruses.</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2022
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Book/collection name
Annual Reports in Medicinal Chemistry
ISBN
978-0-323-98893-3
Number of pages of the result
38
Pages from-to
55-92
Number of pages of the book
268
Publisher name
Academic Press
Place of publication
USA, UK
UT code for WoS chapter
—